Sensidose is a pharmaceutical company. The company has developed a system for individualized dosing of tablets, a medical treatment using a dosing device pre-programmed for the patient. The company's product portfolio includes a number of brands and drugs intended for the treatment of, for example, Parkinson's. The main operations are in the Nordic region.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Navamedic ASA | 96,33 | 96,33 | 2023-05-26 |
| Yvonne Håkansson | 4,20 | 4,20 | 2023-03-29 |
| Håkan Englund | 2,91 | 2,91 | 2023-03-29 |
| Anders Lundmark | 2,76 | 2,76 | 2023-03-29 |
| Abix Life AB | 2,43 | 2,43 | 2023-03-29 |
| Avanza Pension | 1,84 | 1,84 | 2023-03-29 |
| Tullbacken AB | 1,32 | 1,32 | 2023-03-29 |
| Uppsala Universitet Invest AB | 1,01 | 1,01 | 2023-03-29 |
| Jacob Kaluski | 0,96 | 0,96 | 2023-03-29 |
| Outi Lundén | 0,84 | 0,84 | 2023-03-29 |
2023-05-30 Extra bolagsstämma 2023
2023-08-18 Delårsrapport 2023-Q2
2023-11-10 Delårsrapport 2023-Q3
2024-02-16 Bokslutskommuniké 2023